Featuring
Ten days after Trump's 2024 win, the besties price the new Washington into Bitcoin, IPOs, prescription-drug ads, Polymarket, and a cabinet built to break things. The hottest exchange is Sacks versus Friedberg on whether drug commercials inform patients or quietly buy softer news coverage. Friedberg has the best all-around episode because he keeps separating useful mechanisms from satisfying villains. Jason takes the cleanest hindsight win: pent-up demand for liquidity did reopen the IPO market in 2025.
Spice rack
Should the United States ban direct-to-consumer prescription-drug advertising?
Original point: Sacks argues that prescription-drug ads should not be allowed because patients cannot directly buy the products and the spending mainly buys favorable news coverage rather than useful consumer information.
What everyone argued
Jason Calacanis
Jason first challenges a ban on free-speech grounds, asking why consumers cannot evaluate legal product advertising. He then moves toward Sacks's influence thesis, arguing that highly paid television hosts and producers may quietly avoid stories that threaten major pharmaceutical advertisers.
David Sacks
Sacks argues that most patients cannot purchase prescription drugs directly, that nearly every peer country bars this advertising, and that the sheer spending is best explained as influence-buying that softens news coverage. He concedes some ads can inform patients but says the corruption risk justifies removing the money.
David Friedberg
Friedberg opposes giving government broad authority to decide who may advertise, argues that consumers can punish untrusted media, and says ads can alert patients to genuinely better treatments such as Ocrevus for multiple sclerosis. He separately blames distorted drug prices on insurance design, middlemen, and regulatory capture rather than advertising alone.
Winner circle
Friedberg wins the policy question because he distinguishes useful awareness from deception and asks government to target the actual failure rather than prohibit the whole channel. Sacks proves that the U.S. regime is unusual and raises a legitimate advertiser-conflict concern, but he does not prove that buying favorable coverage is the primary purpose of drug advertising. The later FDA crackdown—strong enforcement and tighter disclosures without a blanket ban—supports the narrower remedy, though Friedberg understates the need for regulation in a market with severe information asymmetry.
Commentary
Jason Calacanis
Assumptions and fact checks
A federal ban on truthful prescription-drug advertising would create a serious free-speech problem.
Why it mattersCommercial speech receives less protection than political speech, but a categorical ban would still require a defensible legal and evidentiary basis. The government has less restrictive tools, including fair-balance rules and enforcement against misleading claims.
Pharmaceutical ad spending commonly causes television newsrooms to avoid negative coverage of drug companies.
Why it mattersThe incentive is credible, but neither the transcript nor the reviewed government evidence quantifies routine newsroom suppression. It should be treated as a conflict-of-interest risk, not a proved general mechanism.
David Sacks
Sacks is right about the unusual U.S. regime and the conflict risk, but his strongest allegation carries the weakest evidence. He treats a plausible media incentive as if it proves the purpose of billions in patient-facing promotion.
Assumptions and fact checks
The primary purpose of pharmaceutical television advertising is to buy favorable news coverage rather than influence patient demand.
Why it mattersGAO describes manufacturers as advertising to encourage consumers to request specific medicines and found possible increases in use and spending. Advertiser influence is a material conflict risk, but the evidence reviewed does not support calling it the primary purpose of the entire category.
A categorical ban is preferable to enforcing truthfulness, fair balance, disclosure, and conflict safeguards.
Why it mattersThe record contains both benefits and harms, which favors targeted enforcement unless stronger evidence shows that narrower controls cannot work. FDA's later crackdown followed that narrower route.
The United States is one of very few countries that permit direct-to-consumer advertising of prescription drugs.
CheckThe Congressional Research Service identifies the United States and New Zealand as the two countries that allow direct-to-consumer prescription-drug advertising.
Consumers generally cannot buy prescription drugs without a clinician's prescription.
CheckFDA defines prescription drugs as prescribed by a doctor and distinguishes them from over-the-counter drugs that do not require a prescription. Patients can still influence demand by asking clinicians for advertised products.
David Friedberg
Friedberg wins because he separates three problems—patient information, media incentives, and drug pricing—instead of making one ban carry all of them. His prescription is incomplete, but it is more proportional than Sacks's.
Assumptions and fact checks
Useful patient awareness and less restrictive enforcement can preserve benefits without a blanket advertising ban.
Why it mattersGovernment reviews find both potential awareness benefits and risks of higher use or spending. Targeting deceptive claims, inadequate risk disclosure, and undisclosed promotion better matches that mixed record.
Consumer migration away from legacy media is enough to correct pharmaceutical advertiser influence.
Why it mattersAudience exit can discipline media brands but does not solve medical information asymmetry or protect viewers who remain. Independent enforcement and transparent conflicts are still needed.
Ocrevus represented a major effective advance for multiple sclerosis patients.
CheckFDA's review found substantial evidence of effectiveness and reported a 46-47% reduction in annualized relapse rate versus Rebif in two controlled trials. Friedberg garbled the drug name as 'acus,' but the context clearly points to Ocrevus.
Government-funded insurance programs do not negotiate drug prices.
CheckThe claim is too broad. By the recording date, CMS had completed direct negotiations with manufacturers for ten high-expenditure Medicare Part D drugs, with negotiated prices scheduled to take effect in 2026; Part D plans and intermediaries also negotiate prices and rebates. Limits and middlemen remain real, but 'do not negotiate' is inaccurate.
Would 2025 finally bring a strong reopening of the U.S. IPO market?
Original point: Chamath predicts that IPO activity will remain subdued, especially in the first half of 2025, because a roughly 4.5% ten-year Treasury yield makes risky, money-losing technology offerings hard to price attractively.
What everyone argued
Chamath Palihapitiya
Chamath argues that the rate backdrop, not election enthusiasm, sets the hurdle. If investors can earn roughly 4.5% in Treasuries, a software or internet company that skipped the zero-rate window has to offer unusually compelling growth or accept a painful valuation; he therefore expects the IPO market to stay fairly subdued.
Jason Calacanis
Jason predicts that exhausted boards, aging venture funds, employees seeking liquidity, and founders willing to take valuation haircuts will push companies into public markets. He points to the recoveries of recent listings as evidence that companies can survive an initially rough debut and earn investor confidence later.
David Friedberg
Friedberg agrees that high Treasury yields make risky assets expensive, but argues that investors were already seeking risk and could pay up for businesses whose future earnings would accelerate under lower taxes or lighter regulation. He therefore sketches a selective reopening rather than either a frozen or indiscriminately booming market.
Winner circle
Jason wins the directional forecast: 2025 produced a real U.S. IPO rebound, and his backlog-and-liquidity mechanism explained how listings could return before rates became cheap. Friedberg's selective-risk model was the best nuance and fits the uneven quality of the reopening. Chamath correctly identified the valuation hurdle and the reluctance of marquee private firms, but his broad subdued-market call missed the full-year result.
Commentary
Chamath Palihapitiya
Chamath identified the right brake but treated it as the whole vehicle. A stronger forecast would have separated total IPO activity from the willingness of the largest venture-backed software names to accept public-market price discovery.
Assumptions and fact checks
A 4.5% ten-year Treasury yield would dominate investor demand strongly enough to keep 2025 IPO activity near its depressed 2022-2024 level.
Why it mattersRates did raise the valuation hurdle, but they did not prevent a large year-over-year increase in offerings and proceeds. Issuer backlog, risk appetite, and willingness to reset valuations proved powerful enough to reopen the market.
The most richly valued private software companies would still find public-market pricing unattractive.
Why it mattersThat narrower warning held up better. The broad market reopened without forcing every famous late-stage company named in the episode to list.
The U.S. IPO market remained subdued in 2025.
CheckAs a full-year forecast, this was wrong: the SEC reports that IPO count rose about 52% and proceeds rose about 79% from 2024 to 2025. EY likewise describes larger deals and aggregate proceeds as increasing, although the recovery was selective rather than a return to 2021 conditions.
Jason Calacanis
Jason wins the forecast by pairing demand with forced supply: old cap tables eventually need an exit even when rates are not friendly. His named-company enthusiasm ran ahead of events, but the aggregate call was right.
Assumptions and fact checks
Liquidity pressure and investor fatigue would make private-company stakeholders accept valuation haircuts and pursue exits in 2025.
Why it mattersThe jump in offering count is consistent with backlog clearing and greater willingness to transact, although aggregate data cannot establish the motivation of every issuer.
A healthier post-listing performance story would persuade more venture-backed companies to file.
Why it mattersImproved public comparables and a functioning issuance window plausibly reduce the perceived risk of listing. Jason would have been stronger with a clearer distinction between evidence available at recording and optimism about future filings.
U.S. IPO activity would rebound strongly in 2025.
CheckThe SEC recorded 374 IPOs raising more than $70 billion in 2025, up from 246 IPOs raising $39 billion in 2024. That is a strong rebound in both count and proceeds, even though it was not a universal exit window for every late-stage technology company.
David Friedberg
Friedberg's selective-reopening model aged well, but he stops short of a clean market forecast. He gets credit for resisting both the zero-rate nostalgia and the idea that a 4.5% Treasury yield freezes all risk-taking.
Assumptions and fact checks
Risk appetite and expected earnings growth could outweigh the high risk-free rate for selected issuers.
Why it mattersThe strong increase in 2025 IPO proceeds supports a selective-risk interpretation. The market was open enough for credible issuers without erasing valuation discipline.
Deregulation would be a broad direct driver of technology-company earnings and exits.
Why it mattersFriedberg himself narrows this point to fintech and other regulated businesses. The aggregate IPO rebound does not isolate deregulation from market levels, issuer quality, backlog, or other causes.
Jason raises the best legal objection and then weakens it by joining an influence-buying theory without evidence proportionate to the accusation. He would have been stronger advocating advertiser disclosure and editorial firewalls.